Cholecystokinin (Cck) Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Cholecystokinin (CCK) neurons are peptide-expressing neuronal populations found in cortex, hippocampus, amygdala, hypothalamus, and multiple subcortical networks. In the CNS, CCK is both a neuropeptide transmitter and a circuit-level modulator that interacts with GABAergic interneurons, endocannabinoid tone, and state-dependent excitability.[1][2]
Cholecystokinin (CCK) neurons represent a diverse population of GABAergic interneurons characterized by their expression of the cholecystokinin peptide. These neurons play crucial roles in modulating anxiety, memory, pain perception, and appetite regulation. In the context of neurodegenerative diseases, CCK neurons are increasingly recognized for their involvement in circuit dysfunction and their potential as therapeutic targets.
Key Characteristics:
CCK-expressing neurons are not a single electrophysiologic class. Important subgroups include:
This diversity matters for disease interpretation: transcript-level CCK shifts can reflect inhibitory circuit remodeling, peptide-state transitions, or both.[2:2][4]
In cortical-hippocampal microcircuits, CCK interneuron subclasses contribute to perisomatic inhibition of principal neurons. Compared with fast-spiking PV systems, CCK-associated inhibition is often more neuromodulator-sensitive and context-gated.[2:3][3:1]
A central feature of many CCK interneurons is high CB1 receptor expression. Retrograde endocannabinoid signaling can transiently suppress GABA release from these terminals, dynamically changing local excitation-inhibition balance during behavior and plasticity.[3:2][5]
CCK pathways influence anxiety-related processing, sensory salience gating, and mnemonic encoding/retrieval states. These effects likely emerge from combined peptide signaling plus rapid GABAergic synaptic actions.[1:1][2:4]
In Alzheimer's disease, inhibitory microcircuit disruption is a recurrent systems finding. CCK-positive inhibitory populations are part of this vulnerability landscape and may contribute to network hyperexcitability, oscillatory desynchronization, and cognitive instability when inhibitory reserve declines.[4:1][6]
In Parkinson's disease, CCK signaling has been linked more strongly to non-motor circuit domains (mood, anxiety, sleep, and cognitive flexibility) than to direct nigrostriatal neurodegeneration. This suggests a modulatory role in symptom expression rather than a primary etiologic role.[1:2][7]
Because CCK systems participate in inhibitory regulation and neuromodulator-sensitive gating, they are relevant to seizure susceptibility and excitability stress states that can coexist with neurodegenerative pathology.[8][9]
Potential intervention axes include:
The strongest current translational case is for circuit-symptom modulation (especially anxiety/arousal domains), while definitive disease-modifying evidence in AD/PD remains limited.[1:3][2:5]
The study of Cholecystokinin (Cck) Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Beinfeld MC. Cholecystokinin in the brain and behavior. Neuropeptides. 2020. ↩︎ ↩︎ ↩︎ ↩︎
Freund TF, Katona I. Perisomatic inhibition and CCK interneuron logic. Neuron. 2007. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Katona I, Sperlágh B, Sík A, et al. CB1 receptors on hippocampal interneuron terminals. J Neurosci. 1999. ↩︎ ↩︎ ↩︎
Verret L, Mann EO, Hang GB, et al. Interneuron deficits and cognitive dysfunction in AD models. Cell. 2012. ↩︎ ↩︎
Wilson RI, Nicoll RA. Endocannabinoid retrograde signaling in hippocampus. Nature. 2001. ↩︎
Palop JJ, Mucke L. Network abnormalities in Alzheimer's disease. Neuron. 2010. ↩︎
Tovote P, Fadok JP, Lüthi A. Neuronal circuits for fear and anxiety. Nat Rev Neurosci. 2015. ↩︎
Trevelyan AJ, Schevon CA. Seizure dynamics and inhibitory network failure. Nat Rev Neurosci. 2013. ↩︎
Ascoli GA, Alonso-Nanclares L, Anderson SA, et al. Interneuron nomenclature and cortical inhibitory classes. Nat Rev Neurosci. 2008. ↩︎